Biocon Ltd. shares may rise following the USFDA's approval of its key diabetes treatment drug, Kristy, potentially enhancing insulin accessibility and affordability.

Biocon announced that its subsidiary, Biocon Biologics, has received US Food and Drug Administration (USFDA) approval for Kirsty (Insulin Aspart-xjhz) 100 units/ml, to improve glycemic control in ...

Currently, Kristy is available in the European Union and Canada markets since 2022. The approval is for the fist and only ...

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL) , a fully int ...

Brazil's Health Ministry took delivery on Friday of the first batch of insulin produced through the Partnerships for ...

Regarding injection site rotation, alternate between different areas like the abdomen, thigh, or upper arm to prevent ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

For almost 1 million New York City residents living with type 2 diabetes, the silence from public officials as they fail to ...

Despite the federal government’s recent implementation of zero import duty on pharmaceuticals and active pharmaceutical ...